Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide

被引:14
作者
Preiss, R
Schmidt, R
Baumann, F
Hanschmann, H
Hauss, J
Geissler, F
Pahlig, H
Ratzewiss, B
机构
[1] Univ Leipzig, Inst Clin Pharmacol, D-04107 Leipzig, Germany
[2] Univ Leipzig, Dept Surg 2, D-04107 Leipzig, Germany
[3] Hosp Berlin Friedrichshain, Dept Surg, Berlin, Germany
关键词
ifosfamide 4-hydroxylation and; N-dechloroethylation reactions; acrolein; keto and carboxyifosfamide; cytochrome p450 isoforms;
D O I
10.1007/s00432-002-0335-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of the present study was to determine the turnover (4-hydroxylation and N-dechloroethylation) of ifosfamide in a total of 25 human liver microsomal preparations in which the codetermination of keto- and carboxyifosfamide as well as the calculation of free and protein-bound acrolein was carried out for the first time. Methods: The 4-hydroxylation of ifosfamide was estimated by using acrolein (free and protein-bound) and a newly developed procedure involving the codetermination of keto- and carboxyifosfamide (LC/MS). The ifosfamide N-dechloroethylation was determined as the sum of 2- and 3-dechloroethylifosfamide (LC/MS). Results: Using the usual estimation of liberated free acrolein in 25 human liver microsomal preparations, the 4-hydroxylation of ifosfamide amounted to 0.28 +/- 0.16 nmol/min (.) nmol(P450). However, after calculating the 4-hydroxylation as the sum of free and protein-bound acrolein and keto- and carboxyifosfamide, a ninefold higher activity (2.40 +/- 0.73 nmol/min . nmol(P450)) was found. The percentage of the inactive metabolites keto- (25/25) and carboxyifosfamide (5/25) in the 4-hydroxylation amounted to only 0.79-5.25% (mean 2.90%). The ifosfamide N-dechloroethylation (mean 0.21 +/- 0.11 nmol/min (.) nmol(P450)) determined as the sum of 2- and 3-dechloroethylifosfamide was estimated as 8.3 +/- 4.3% of the total ifosfamide turnover. The application of the relative substrate-activity factor (RSF)-approach and the calculation of the contribution of various isoforms in the ifosfamide 4-hydroxylation yielded the following results: CYP 3A4: 58 +/- 31%, CYP 2A6: 25 +/- 15%, and CYP 2C9: 5 +/- 2% of the total measured 4-hydroxylation. A correlation between 4-hydroxylation and the N-dechloroethylation rates of ifosfamide and the activities of isoenzymes indicates the involvement of both CYP 3A4 (P=0.026) and CYP 2C9 (P=0.012) in the 4-hydroxylation reaction and of CYP 3A4 (P<0.01) in the N-dechloroethylation reaction. Conclusions: The estimation of protein-bound acrolein should be included in the calculation of the ifosfamide 4-hydroxylation besides liberated free acrolein. Because of the small amounts of the inactive metabolites keto- and carboxyifosfamide, the exclusive determination of acrolein only (free and protein-bound) seems to suffice for the calculation of total ifosfamide hydroxylation. Using this method the hepatic in vitro turnover of ifosfamide was estimated as 92% for 4-hydroxylation (CYP 3A4 and CYP 2A6 mediated) and 8% for N-dechloroethylation (CYP 3A4 mediated), and in this way, a relative overestimation of the N-dechloroethylation of ifosfamide on the whole metabolism is avoided.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 20 条
[1]   Cyclophosphamide and related anticancer drugs [J].
Baumann, F ;
Preiss, R .
JOURNAL OF CHROMATOGRAPHY B, 2001, 764 (1-2) :173-192
[2]   High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes [J].
Bohnenstengel, F ;
Eichelbaum, M ;
Golbs, E ;
Kroemer, HK .
JOURNAL OF CHROMATOGRAPHY B, 1997, 692 (01) :163-168
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   ETHOXYPHENOXAZONES, PENTOXYPHENOXAZONES, AND BENZYLOXYPHENOXAZONES AND HOMOLOGS - A SERIES OF SUBSTRATES TO DISTINGUISH BETWEEN DIFFERENT INDUCED CYTOCHROMES-P-450 [J].
BURKE, MD ;
THOMPSON, S ;
ELCOMBE, CR ;
HALPERT, J ;
HAAPARANTA, T ;
MAYER, RT .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (18) :3337-3345
[5]  
CHANG TKH, 1993, CANCER RES, V53, P5629
[6]   Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation [J].
Chang, TKH ;
Yu, L ;
Goldstein, JA ;
Waxman, DJ .
PHARMACOGENETICS, 1997, 7 (03) :211-221
[7]  
Granvil CP, 1999, DRUG METAB DISPOS, V27, P533
[8]   Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide [J].
Huang, ZQ ;
Roy, P ;
Waxman, DJ .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (08) :961-972
[9]  
Jounaidi Y, 1998, CANCER RES, V58, P4391
[10]  
MASUREL D, 1990, CANCER RES, V50, P252